President Donald Trump has escalated efforts to persuade Food and Drug Administration Commissioner Marty Makary to shift agency policy and authorize flavored nicotine products, people familiar with the matter told reporters. The president chastised the commissioner over the weekend for what he perceives as insufficient speed on a central agenda item for his administration.
Markets reacted quickly to the prospect that the FDA might relax restrictions on flavored vapes. After the initial report, shares of Turning Point Brands Inc (NYSE:TPB) climbed 3.2% and British American Tobacco PLC ADR (NYSE:BTI) rose 1.7%. Philip Morris International Inc (NYSE:PM) and Altria Group (NYSE:MO) pared earlier losses following the report.
Pressure and meetings
According to sources, the pressure peaked during a sequence of calls from Florida and White House meetings on Monday. Those discussions reportedly included advisers pressing the case that approving flavored vaping products carries particular political weight with young MAGA voters, and that Makary's performance warranted close review.
White House aides have characterized the commissioner as a substantial impediment to the president's pro-vaping policy objectives. They noted that Makary previously declined to approve menthol, mango, and blueberry flavors from Los Angeles manufacturer Glas, a decision that ran counter to administration preferences.
Where things stand with the commissioner
Following the weekend admonishment and subsequent conversations, the two men have discussed whether to alter course. It remains unclear if a definitive decision has been reached. Some sources said Makary is contemplating becoming more receptive to authorizing flavors despite his longstanding public-health concerns.
The commissioner's earlier reluctance stems from the worry that fruit and candy flavors may disproportionately attract children, potentially worsening youth nicotine addiction rates. He has historically sought to avoid greenlighting any products that could elevate youth use.
Regulatory backdrop and wider agency criticism
The FDA has maintained a generally restrictive posture for years, typically confining authorizations to tobacco and menthol-flavored products. That cautious approach has persisted across administrations and has left most of the flavored market in regulatory uncertainty.
Beyond the vaping debate, Makary's standing inside the administration is said to be fragile because of separate frustrations over drug approvals. The commissioner has faced criticism for recent rejections of rare-disease treatments, prompting outreach efforts designed to mend ties with influential figures in the pharmaceutical sector.
Those outreach efforts are occurring as the White House signals growing impatience with the agency's pace and direction on multiple fronts.
Investor implications
For investors, a change in FDA policy on flavored products would be a substantial development for the valuation outlook of both legacy tobacco companies and specialized vaping firms. Observers in the market say that formal authorization of fruit and dessert flavors could free a revenue stream that has been constrained by years of federal enforcement.
At the same time, uncertainty over whether the commissioner will change course - and how quickly any policy shift would be implemented - leaves market participants weighing both the potential upside and the regulatory risks that remain embedded in these equities.
Summary
President Trump has pressured FDA Commissioner Marty Makary to approve flavored nicotine products, prompting immediate positive movement in certain nicotine-related stocks. The White House views flavored vapes as politically important to parts of its base, while the commissioner has traditionally resisted flavor authorizations due to youth public-health concerns. Makary is reportedly considering a more permissive stance, but no conclusive decision has been reported. The episode occurs amid broader dissatisfaction within the administration about the agency's handling of drug approvals and its overall pace.